Ischemia Technologies raises $10.3 million:
This article was originally published in Clinica
Executive Summary
Ischemia Technologies has privately raised $10.3 million. The Denver, Colorado company will use the fresh funds to accelerate product development and launch its tests in Europe and the US. Ischemia has an albumin cobalt binding (ACB) test, which is under review by the FDA. The company claims the test, when used in conjunction with troponin, shows better sensitivity and earlier identification of patients with acute myocardial infarction than troponin alone.